Skip to main content

Research Repository

Advanced Search

Bioactivity of compounds derived from Amaryllicaea (Daffodil)

People Involved

Project Description

Heart Failure (HF) is a long-term complication of cardiovascular (high blood pressure and heart attack) and cardiovascular-related (obesity and metabolic syndrome) disorders and of drug-induced cardiotoxicity. HF is characterised by thickening (hypertrophy) and stiffening (fibrosis) of the walls of the heart, leading to reduced cardiac function and increased morbidity. Agroceutical Products Ltd (APL) produces sustainable quantities of the naturally derived alkaloid galanthamine from daffodils, which is a key active pharmaceutical used for the treatment of Alzheimer’s disease. Daffodils contain an abundance of other alkaloid compounds, some of which (e.g. narciclasine and haemanthamine) APL can extract alongside galanthamine. There is emerging evidence that some of these alkaloids may target cellular events in the heart cell (cardiomyocyte) to interrupt the HF-associated structural changes, and thus have the potential for development as novel therapeutics in the prevention of HF. This project will involve testing three alkaloids extracted from daffodils in cell-based cardiomyocyte models that mimic the different stimuli for cardiac hypertrophy (high glucose, oxidative stress and doxorubicin), to determine their potential as anti-hypertrophic/anti-fibrotic molecules, and by measuring multiple cellular signalling pathways we will gain insight into cellular mechanism of action. This will provide essential “proof of concept” data that will identify the most efficacious compounds, inform the refinement of extraction methods to isolate different alkaloids, and potentially identify what structure-activity relationships may exist between alkaloids. This will inform APL as to which alkaloids have the potential to bring added value to their current production stream which will, in turn maximise the commercial potential for their products.

Status Project Complete
Funder(s) Industrial Biotechnology Innovation Centre
Value £39,958.00
Project Dates Feb 1, 2021 - Jul 31, 2022
Partner Organisations Agroceutical Products Ltd

You might also like

A human Glutathione Peroxidase 4 3 untranslated region knock-in mouse model to study susceptibility to colon cancer in obesity Apr 1, 2017 - Dec 31, 2021
Colorectal cancer (CRC) incidence is rising steadily and in parallel with increasing prevalence of obesity in Scotland. Recent data indicate that the highest incidence rates are in the North East. The increasing prevalence of obes... Read More about A human Glutathione Peroxidase 4 3 untranslated region knock-in mouse model to study susceptibility to colon cancer in obesity.

The in vitro effect of natural products and anti-cancer agents: targeting the efflux transporter ABCG2 Jul 1, 2017 - Dec 31, 2019
Medicinal use of natural products, such as, extracts from plants have existed for many years particularly in China and are now widely available around the world. Several different types of cancer including breast cancer are becoming insensitive and r... Read More about The in vitro effect of natural products and anti-cancer agents: targeting the efflux transporter ABCG2.